相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion
David Ermert et al.
JOURNAL OF IMMUNOLOGY (2018)
Development of an opsonophagocytic killing assay for group a streptococcus
Scott Jones et al.
VACCINE (2018)
Interlaboratory Comparison of the Pneumococcal Multiplex Opsonophagocytic Assays and Their Level of Agreement for Determination of Antibody Function in Pediatric Sera
A. Balloch et al.
MSPHERE (2018)
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015
David A. Watkins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Status of research and development of vaccines for Streptococcus pyogenes
Andrew C. Steer et al.
VACCINE (2016)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohsen Naghavi et al.
LANCET (2015)
Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus
Shu Ki Tsoi et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Mark J. Walker et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
Martina Sanderson-Smith et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Non-Immune Binding of Human IgG to M-Related Proteins Confers Resistance to Phagocytosis of Group A Streptococci in Blood
Harry S. Courtney et al.
PLOS ONE (2013)
Potential coverage of a multivalent M protein-based group A streptococcal vaccine
James B. Dale et al.
VACCINE (2013)
Group A streptococcal vaccines: Paving a path for accelerated development
James B. Dale et al.
VACCINE (2013)
New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci
James B. Dale et al.
VACCINE (2011)
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development
Andrew C. Steer et al.
LANCET INFECTIOUS DISEASES (2009)
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies
Robert L. Burton et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor
HT Jenkins et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The global burden of group A streptococcal diseases
JR Carapetis et al.
LANCET INFECTIOUS DISEASES (2005)
Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers
SA McNeil et al.
CLINICAL INFECTIOUS DISEASES (2005)
Prospects for a group a streptococcal vaccine: Rationale, feasibility, and obstacles - Report of a national institute of allergy and infectious diseases workshop
AL Bisno et al.
CLINICAL INFECTIOUS DISEASES (2005)
Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults - Phase 1 trial
KL Kotloff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Immunogenicity of a 26-valent group A streptococcal vaccine
MC Hu et al.
INFECTION AND IMMUNITY (2002)
Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity
J Martinez et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2002)
分享论文
